Orbactiv
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Orbactiv is a broad-spectrum antibiotic mainly targeting inpatient settings. The drug is a semisynthetic lipoglycopeptide that inhibits bacterial cell wall synthesis by blocking peptidoglycan biosynthesis. Orbactiv mainly inhibits bacterial transglycosylase, which is the enzyme that forms the glycan backbone of the cell wall. Secondly, it inhibits transpeptidase, an enzyme that cross-links adjacent glycan strands to form the cell wall. Orbactiv has demonstrated in vitro bactericidal activity against a wide range of Gram-positive bacterial strains. It has demonstrated potency against vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA). Moreover, it is active against both the VanA and VanB phenotypes of vancomycin-resistant enterococcus (VRE). Orbactiv’s enhanced efficacy stems partially from its additional ability to directly disrupt the bacterial cell wall and increase its permeability.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Orbactiv : Skin and skin structure infections
LIST OF FIGURES
10 Figure 1: Orbactiv’s SWOT analysis in cSSSI
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of Orbactiv in cSSSI
12 Figure 3: Datamonitor Healthcare’s drug assessment summary for Orbactiv in cSSSI
LIST OF TABLES
4 Table 1: Orbactiv’s drug profile in ABSSSI
6 Table 2: Overview of pivotal trial data for Orbactiv in ABSSSI
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Cubicin 
Sign up to the